Sepsis 28-day mortality
A 2025 systematic review and meta-analysis of 11 randomised controlled trials (1,927 adult sepsis, severe sepsis and septic shock patients) found thymosin alpha-1 associated with reduced 28-day mortality overall (odds ratio 0.73, 95% CI 0.59 to 0.90, p=0.003), but this benefit was not statistically significant when restricted to high-quality studies alone (odds ratio 0.82, 95% CI 0.65 to 1.03, p=0.09) or to multi-centre studies alone (odds ratio 0.86, 95% CI 0.68 to 1.08, p=0.20). Trial sequential analysis indicated the current evidence base is statistically underpowered and at risk of false-positive conclusions; publication bias was detected.
- Study type
- Human trial
- Population
- Adult sepsis, severe sepsis and septic shock patients, 11 pooled randomised controlled trials, all China-based, 1,927 total patients
- Source
- 1 Gu et al., 2025
Limitation: All 11 trials China-based; small individual trial sizes; combination-therapy trials excluded; sepsis diagnostic criteria inconsistent across the trials' publication years; detected publication bias.
Limitations in full
All 11 trials China-based; small individual trial sizes; combination-therapy trials excluded; sepsis diagnostic criteria inconsistent across the trials' publication years; detected publication bias. This is a genuinely mixed finding, not a clean positive: the headline pooled result and the quality-restricted result disagree, and both are stated here.